GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Micro Biosystems Inc (NAS:RPID) » Definitions » Piotroski F-Score

RPID (Rapid Micro Biosystems) Piotroski F-Score : 3 (As of Mar. 16, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Rapid Micro Biosystems Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rapid Micro Biosystems has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Rapid Micro Biosystems's Piotroski F-Score or its related term are showing as below:

RPID' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 5
Current: 3

During the past 6 years, the highest Piotroski F-Score of Rapid Micro Biosystems was 5. The lowest was 2. And the median was 3.


Rapid Micro Biosystems Piotroski F-Score Historical Data

The historical data trend for Rapid Micro Biosystems's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Micro Biosystems Piotroski F-Score Chart

Rapid Micro Biosystems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial N/A 5.00 2.00 3.00 3.00

Rapid Micro Biosystems Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 3.00 3.00

Competitive Comparison of Rapid Micro Biosystems's Piotroski F-Score

For the Medical Devices subindustry, Rapid Micro Biosystems's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Micro Biosystems's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Rapid Micro Biosystems's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was -13.322 + -12.578 + -11.323 + -9.666 = $-46.89 Mil.
Cash Flow from Operations was -15.525 + -10.119 + -8.6 + -9.909 = $-44.15 Mil.
Revenue was 5.611 + 6.618 + 7.604 + 8.218 = $28.05 Mil.
Gross Profit was -1.523 + -0.189 + 0.622 + 0.981 = $-0.11 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(143.452 + 127.731 + 117.085 + 105.843 + 98.169) / 5 = $118.456 Mil.
Total Assets at the begining of this year (Dec23) was $143.45 Mil.
Long-Term Debt & Capital Lease Obligation was $4.95 Mil.
Total Current Assets was $80.92 Mil.
Total Current Liabilities was $17.57 Mil.
Net Income was -13.887 + -14.016 + -13.392 + -11.172 = $-52.47 Mil.

Revenue was 5.035 + 5.002 + 6.145 + 6.337 = $22.52 Mil.
Gross Profit was -1.79 + -1.892 + -1.631 + -0.172 = $-5.49 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(190.65 + 173.281 + 160.945 + 150.164 + 143.452) / 5 = $163.6984 Mil.
Total Assets at the begining of last year (Dec22) was $190.65 Mil.
Long-Term Debt & Capital Lease Obligation was $6.21 Mil.
Total Current Assets was $120.42 Mil.
Total Current Liabilities was $18.99 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rapid Micro Biosystems's current Net Income (TTM) was -46.89. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rapid Micro Biosystems's current Cash Flow from Operations (TTM) was -44.15. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=-46.889/143.452
=-0.32686195

ROA (Last Year)=Net Income/Total Assets (Dec22)
=-52.467/190.65
=-0.27520063

Rapid Micro Biosystems's return on assets of this year was -0.32686195. Rapid Micro Biosystems's return on assets of last year was -0.27520063. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Rapid Micro Biosystems's current Net Income (TTM) was -46.89. Rapid Micro Biosystems's current Cash Flow from Operations (TTM) was -44.15. ==> -44.15 > -46.89 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=4.954/118.456
=0.04182144

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=6.214/163.6984
=0.03796005

Rapid Micro Biosystems's gearing of this year was 0.04182144. Rapid Micro Biosystems's gearing of last year was 0.03796005. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=80.917/17.565
=4.6067179

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=120.415/18.986
=6.34230486

Rapid Micro Biosystems's current ratio of this year was 4.6067179. Rapid Micro Biosystems's current ratio of last year was 6.34230486. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Rapid Micro Biosystems's number of shares in issue this year was 43.77. Rapid Micro Biosystems's number of shares in issue last year was 43.141. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-0.109/28.051
=-0.00388578

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-5.485/22.519
=-0.24357209

Rapid Micro Biosystems's gross margin of this year was -0.00388578. Rapid Micro Biosystems's gross margin of last year was -0.24357209. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=28.051/143.452
=0.19554276

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=22.519/190.65
=0.11811697

Rapid Micro Biosystems's asset turnover of this year was 0.19554276. Rapid Micro Biosystems's asset turnover of last year was 0.11811697. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rapid Micro Biosystems has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Rapid Micro Biosystems  (NAS:RPID) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Rapid Micro Biosystems Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Rapid Micro Biosystems's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Micro Biosystems Business Description

Traded in Other Exchanges
N/A
Address
1001 Pawtucket Boulevard West, Suite 280, Lowell, MA, USA, 01854
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Executives
Melinda Litherland Pei director 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Sean M Wirtjes officer: Chief Financial Officer C/O VARIAN, INC., 3120 HANSEN WAY, M/S D-083, PALO ALTO CA 94304-1030
Spignesi Robert G. Jr. director, officer: President and CEO C/O RAPID MICRO BIOSYSTEMS, INC., 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Richard S Kollender director C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
Kennedy Lewis Capital Partners Master Fund Ii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Darren Richman 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Klm Gp Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Investment Management Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Management Lp 10 percent owner 225 LIBERTY STREET, SUITE 4210, NEW YORK NY 10281
David Chene 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Capital Partners Master Fund Iii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Iii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Holdings Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120